摘要
Objective:The aim of our study was to evaluate the serum levels of CA19-9 in patients with non-small cell lung cancer(NSCLC)and to analyze the relationship between serum levels of CA19-9 and metastasis.Methods:Serum levels of CA19-9 in 1200 NSCLC patients from February 2006 to August 2011 were evaluated retrospectively.The relationship between serum levels of CA19-9 and sites of metastasis were analyzed.Results:Of the 1200 patients,528 were stage IV and the positive rate of CA19-9 was 32%(169 cases)and 288 stage III,positive rate 20%(58 cases);144 stage II,positive rate 12%(17 cases);240 stage I,positive rate 3%(7 cases).There were statistical differences from stage I to stage IV(P<0.01).The total positive rate in the 1200 cases was 21%.Furthermore,of the 528 stage IV cases,350 had bone metastasis and the positive rate of CA19-9 was 43%(150 cases)in bone metastatic cases.In turn,in CA19-9 positive patients(169 cases)of stage IV, the positive rate of bone metastasis was 89%(150/169).There was no statistical difference of positive rate of CA19-9 between adenocarcinoma and squamous carcinoma(P>0.05).Conclusion:Positive rate of CA19-9 increases accordingly from stage I to stage IV.The serum levels of CA19-9 may be as an indicator for metastases in patients with NSCLC,especially for bone metastasis in stage IV diseases.
Objective: The aim of our study was to evaluate the serum levels of CA19-9 in patients with non-small cell lung cancer (NSCLC) and to analyze the relationship between serum levels of CA19-9 and metastasis. Methods: Serum levels of CA19-9 in 1200 NSCLC patients from February 2006 to August 2011 were evaluated retrospectively. The relationship between serum levels of CA19-9 and sites of metastasis were analyzed. Results: Of the 1200 patients, 528 were stage IV and the posi- tive rate of CA19-9 was 32% (169 cases) and 288 stage III, positive rate 20% (58 cases); 144 stage II, positive rate 12% (17 cases); 240 stage I, positive rate 3% (7 cases). There were statistical differences from stage I to stage IV (P 〈 0.01). The total positive rate in the 1200 cases was 21%. Furthermore, of the 528 stage IV cases, 350 had bone metastasis and the positive rate of CA19-9 was 43% (150 cases) in bone metastatic cases. In turn, in CA19-9 positive patients (169 cases) of stage IV, the positive rate of bone metastasis was 89% (150/169). There was no statistical difference of positive rate of CA19-9 between adenocarcinoma and squamous carcinoma (P 〉 0.05). Conclusion: Positive rate of CA19-9 increases accordingly from stage I to stage IV. The serum levels of CA19-9 may be as an indicator for metastases in patients with NSCLC, especially for bone metastasis in stage IV diseases.